eFFECTOR Appoints Mayank Gandhi, M.D., as Chief Business Officer Portfolio News / Karina Tin September 26, 2022 eFFECTOR Appoints Mayank Gandhi, M.D., as Chief Business Officer Read More »
Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy Portfolio News / Karina Tin September 26, 2022 Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy Read More »
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor Portfolio News / Karina Tin September 22, 2022 Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor Read More »
Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy Portfolio News / Karina Tin September 21, 2022 Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy Read More »
Carmot Therapeutics Announces Significant Leadership Team Expansion with Anne Phillips, MD, FRCPC Previously SVP Novo Nordisk, Joining the Board of Directors and Heather Turner, J.D. Joining as COO Portfolio News / Karina Tin September 21, 2022 Carmot Therapeutics Announces Significant Leadership Team Expansion with Anne Phillips, MD, FRCPC Previously SVP Novo Nordisk, Joining the Board of Directors and Heather Turner, J.D. Joining as COO Read More »
Atavistik Bio Announces Formation of Scientific Advisory Board Portfolio News / Karina Tin September 20, 2022 Atavistik Bio Announces Formation of Scientific Advisory Board Read More »
eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19 Portfolio News / Karina Tin September 14, 2022 eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19 Read More »
Nura Bio reports preclinical data validating a conserved mechanism of inhibition of NAD hydrolases implicated in neurodegeneration in NEURON Portfolio News / Karina Tin September 13, 2022 Nura Bio reports preclinical data validating a conserved mechanism of inhibition of NAD hydrolases implicated in neurodegeneration in NEURON Read More »
NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer at AACR Special Conference Portfolio News / Karina Tin September 13, 2022 NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer at AACR Special Conference Read More »
Synthekine Named by Fierce Biotech as one of its “Fierce 15” Biotech Companies of 2022 Portfolio News / Karina Tin September 12, 2022 Synthekine Named by Fierce Biotech as one of its “Fierce 15” Biotech Companies of 2022 Read More »
